碳离子放疗用于不可切除局部复发直肠癌的单中心经验
该单中心回顾性研究分析了25例中国不可切除局部复发直肠癌患者接受碳离子放疗(CIRT)的疗效与安全性。中位随访19.6个月,1年、2年局部控制率分别为90.4%和71.8%,1年、2年总生存率分别为82.9%和65.1%。处方剂量≥66 Gy(RBE)者局部控制率显著优于<66 Gy(RBE)者(P=0.001),急性毒性均≤2级,3级晚期毒性3例,无≥4级毒性。
要点
- CIRT对不可切除局部复发直肠癌有效,1年局部控制率90.4%。
- 处方剂量≥66 Gy(RBE)者局部控制率显著更优(P=0.001)。
- 毒性可接受,无急性>2级毒性,3级晚期毒性3例。
核心结论
- CIRT对不可切除局部复发直肠癌有效且毒性可接受。
研究设计与样本
- 单中心回顾性分析2015年7月至2019年4月收治的25例不可切除局部复发直肠癌患者,均接受CIRT。
- 研究终点为总生存(OS)、局部控制(LC)及急性和晚期毒性。
主要发现
- 中位随访19.6个月(范围5.1-52.5个月),25例患者数据完整。
- 肿瘤中位处方剂量为72 Gy(RBE)(范围48-75.6 Gy(RBE))。
- 1年和2年局部控制率分别为90.4%和71.8%。
- 处方剂量<66 Gy(RBE)的9例患者1年和2年局部控制率分别为76.2%和30.5%;≥66 Gy(RBE)的16例患者均为100%和100%。
- 处方剂量≥66 Gy(RBE)者局部控制率显著优于<66 Gy(RBE)者(P=0.001)。
关键数值与推荐
- 未观察到>2级急性毒性。
- 3例患者出现3级晚期毒性:胃肠道毒性(n=1)、神经病变(n=1)、盆腔感染(n=1)。
- 未观察到4级或更高等级毒性。
临床怎么用
- 对于不可切除局部复发直肠癌,CIRT是可考虑的有效治疗选择。
- 处方剂量≥66 Gy(RBE)与更好的局部控制相关,但需结合临床谨慎评估。
局限性
- 单中心回顾性研究,样本量25例,随访时间有限。
- 剂量比较为回顾性亚组分析,非随机对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment for locally recurrent rectal cancer after surgery is still a challenge. With the physical and biological advantages, carbon-ion radiotherapy (CIRT) could be a choice for these patients. The purpose of this study was to investigate the efficacy and safety of CIRT for unresectable locally recurrent rectal cancer in Chinese patients. METHODS: Date from 25 patients with unresectable locally recurrent rectal cancer treated by CIRT from July 2015 to April 2019 were analyzed retrospectively. The endpoints of this study were overall survival (OS), local control (LC) and acute and late toxicity. RESULTS: With the median follow-up of 19.6 (range 5.1-52.5) months, data of all 25 patients were collected. Median prescribed dose for tumor was 72Gy (relative biologic efficacy (RBE)) (range 48-75.6Gy (RBE)). The LC rates at 1 and 2 years were 90.4 and 71.8%. Overall LC at 1- and 2-year were 76.2 and 30.5% for 9 patients whose prescribed tumor doses of CIRT< 66 Gy (RBE), 100 and 100% for 16 patients whose prescribed doses of CIRT≥66 Gy (RBE). Patients received ≥66 Gy (RBE) had obviously better LC rates than those received < 66 Gy (RBE) (P = 0.001). The OS rates at 1 and 2 years were 82.9 and 65.1%, respectively. No acute toxicity over grade 2 was observed, grade 3 late toxicity were observed in 3 patients: gastrointestinal toxicity (n = 1), neuropathy (n = 1), pelvic infection (n = 1). No Grade 4 or higher toxicity was observed. CONCLUSION: Our study shows that CIRT is effective for unresectable locally recurrent rectal cancer patients with acceptable toxicity.
引用
- Cai X, Du Y, Wang Z, et al. The role of carbon ion radiotherapy for unresectable locally recurrent rectal cancer: a single institutional experience. Radiat Oncol. 2020. PMID: 32859234. doi:10.1186/s13014-020-01653-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。